Abstract
Objective Patients with kidney failure have notoriously weak responses to common vaccines. Thus, immunogenicity of novel SARS-CoV-2 vaccines might be impaired in this group. To determine immunogenicity of SARS-CoV-2 vaccination in patients with chronic dialysis, we analyzed the humoral and T-cell response after two doses of mRNA vaccine Tozinameran (BNT162b2 BioNTech/Pfizer).
Design, Settings, and Participants This observational study included 43 patients on dialysis before vaccination with two doses of Tozinameran 21 days apart. Overall, 36 patients completed the observation period. Serum samples were analyzed by SARS-CoV-2 specific antibodies ∼1 and ∼3-4 weeks after the second vaccination. In addition, SARS-CoV-2-specific T-cell responses were assessed at the later time point by an interferon-gamma release assay (IGRA). Outcomes at later timepoints were compared to a group of 44 elderly patients with no dialysis after immunization with Tozinameran.
Exposures Blood drawings during regular laboratory routine assessment right before start of dialysis therapy or at the time of vaccination and at follow-up study visits.
Main Outcomes and Measures Assessment of immunogenicity after vaccination against SARS-CoV-2 in patients on and without dialysis.
Results Median age of patients on chronic dialysis was 74.0 years (IQR 66.0, 82.0). The proportion of males was higher (69.4%) than females. Only 20/36 patients (55.6%, 95%CI: 38.29-71.67) developed SARS-CoV-2-IgG antibodies at first sampling, whereas 32/36 patients (88.9%, 95%CI:73.00-96.38) demonstrated seropositivity at the second sampling. Seroconversion rates and antibody titers were significantly lower compared to a cohort of vaccinees with similar age but no chronic dialysis (>90% seropositivity). SARS-CoV-2-specific T-cell responses 3 weeks after second vaccination were detected in 21/31 vaccinated dialysis patients (67.7%, 95%CI: 48.53-82.68) compared to 42/44 (93.3%, 95%CI: 76.49-98.84) in controls of similar age.
Conclusion and Relevance Patients on dialysis demonstrate a delayed, but robust immune response three weeks after the second dose, which indicates effective vaccination of this vulnerable group. However, the lower immunogenicity of Tozinameran in these patients needs further attention to develop potential countermeasures such as an additional booster vaccination.
Competing Interest Statement
VMC is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. All other authors declare that they have no competing interests.
Clinical Trial
Not applicable
Funding Statement
Parts of the work was funded by the German Ministry of Research through the projects VARIPath (01KI2021) to VMC, and NaFoUniMedCovid19-COVIM, FKZ: 01KX2021 to LES, FK, and VMC. VMC and ES are participants in the BIH-Charite Clinician Scientist Program funded by the Charite-Universitaetsmedizin Berlin and the Berlin Institute of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local institutional review board of the ethics committee of Charite-Universitaetsmedizin Berlin, Germany (approval number EA4/188/20) and by the local ethics committee of Sachsen-Anhalt (EA7/21). The testing of non-dialysis control subjects is part of ongoing studies on SARS-CoV-2 infection and immunogenicity of COVID-19 vaccines in elderly people and healthcare workers under Charite ethical review board file numbers EA1/068/20, EA4/244/20, and EA4/245/20. Written informed consent was obtained from all patients and healthy volunteers before inclusion in the studies.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are given within the manuscript.
